Dna mutations in egfr as detected by polymerase chain reaction pcr can occur in regions corresponding to the extracellular or intracellular portions of the protein. Patient and methods this was a multicenter, singlearm. Pdf egfr mutation analysis in sputum of lung cancer. Lung cancer is a type of cancer that starts in the lungs. Lung cancer with epidermal growth factor receptor gene egfr mutations accounts for 1020% and 4050% of nsclc cases in caucasians and east asians, respectively 5. Nonsmallcell lung cancer nsclc has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. Summary mutations of the epidermal growth factor receptor egfr gene have been identified in specimens from patients with nonsmallcell lung cancer who have a response to anilinoquinazoline. Mutations within the tyrosine kinase domain of egfr gene. Erlotinib and bevacizumab in patients with advanced non. Nonsmall cell lung cancer nsclc presenting with miliary intrapulmonary carcinomatosis mipc is rare. Inframe deletions around the lrea motif of exon 19 and exon 21 l858r point mutation, which are classic hotspot egfr mutations, ac. Comutations in egfr driven nonsmall cell lung cancer the lancet. Mutations in the tyrosine kinase domain of egfr encoded by exons 1824 have mostly been found in lung cancers.
Gefitinib or erlotinib vs chemotherapy for egfr mutation. Purpose approximately 10% of patients with epidermal growth factor receptor egfr mutation positive nonsmallcell lung cancer nsclc harbor uncommon mutations. From june 2004 to december 2008, we screened newly diagnosed nsclc patients for. Thatcher n, hirsch fr, luft av, szczesna a, ciuleanu te, dediu m, et al. Egfr mutations were found in additional lung cancer samples from u. Osimertinib for untreated egfr mutationpositive nonsmall. E746a750 comprise up to 86% of all egfr mutations in some studies 25. Although recent headtohead clinical trials have demonstrated. Epidermal growth factor receptor egfr mutations in lung cancer. Gefitinib or erlotinib vs chemotherapy for egfr mutation positive lung cancer. Therapeutic responses of nonsmall cell lung carcinoma nsclc to epidermal growth factor receptor egfr targeted drugs, such as gefitinib and erlotinib, are closely associated with activating egfr mutations.
Epidermal growth factor receptor egfr is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Epidermal growth factor receptor egfr mutant nonsmall cell lung cancers nsclc are commonly adenocarcinomas in never smokers. The molecular mechanism by which epidermal growth factor receptortyrosine kinase inhibitors egfr tki induce apoptosis in nonsmall cell lung cancer nsclc cells that are positive for activating mutations of the egfr remains unclear. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as firstline therapy in patients with stage iv squamous nonsmallcell lung cancer squire. Tumor mutation burden and efficacy of egfrtyrosine kinase. Detection of plasma egfr mutations for personalized. Feb 04, 2010 mutations in epidermal growth factor receptor have been discovered in association with some lung cancers. Individual patient data metaanalysis of overall survival article in journal of the national cancer institute 1096.
Mutations of the epidermal growth factor receptor egfr gene have been identified in specimens from patients with nonsmallcell lung cancer who have a response to anilinoquinazoline egfr. Comprehensive biomarker testing can determine whether an egfr lung cancer mutation or another lung cancer mutation is present. Aug 22, 2019 as such, incremental gains in knowledge for this subset of lung cancer are relevant and timely, given the emergence of a proliferation of ici therapies to the therapeutic armamentarium for lung cancer, and the question arises of treatment sequencing and best combinations. Activating mutations in the epidermal growth factor receptor egfr gene have been identified in 1040% of the patients with nonsmallcell lung cancer nsclc, and egfr inhibition leads to suppression of downstream signalling pathways such as mitogenactivated protein kinase mapk and akt protein kinase pathways. Somatically acquired mutations in the epidermal growth factor receptor egfr gene in lung cancer are associated with significant clinical responses to gefitinib. Clinical correlation and outcome to egfr targeted therapy. Lung adenocarcinomas with mutated epidermal growth factor receptor have significant responses to tyrosine kinase inhibitors, although for unselected patients it does not appear to have a survival benefit. Lately, the use of specific antibodies to study the most prevalent of these. Given that more than 60% of nonsmall cell lung carcinomas nsclcs express egfr, egfr has become an important therapeutic target for the treatment of these tumors. We investigated the clinical characteristics and epidermal growth factor receptor egfr mutation rate of nsclc patients with mipc at initial diagnosis. Epidermal growth factor receptor egfr in lung cancer. Molecular diagnosis of activating egfr mutations in non. Epidermal growth factor receptor egfr is expressed in 50% of nsclcs, and its expression is.
Unlike somatic egfr mutations, reported more often in asians, females and nonsmokers, few data for patients harbouring egfr germline mutations are available. The tissue samples of the lung cancer patients were collected bronchoscopically. Somatic epidermal growth factor receptor egfr mutations are now routinely integrated in the molecular diagnosis of nonsmall cell lung cancers nsclc 1, 2. Egfr mutations in patients with brain metastases from lung cancer. Frequent egfr mutations in nonsmall cell lung cancer. Egfr, nsclc, cytological samples, mutation test, arms. Egfr mutated lung cancer means theres been a change mutation to the egfr protein and this mutation makes cancer cells grow. Management of egfrmutation positive metastatic non. The study of epidermal growth factor receptor mutations has become essential for the treatment of lung cancer. Mutational activation of the epidermal growth factor receptor egfr gene is implicated in lung cancer.
Unlike one of our cases, the germline v843i mutation has been reported in a family with lung cancer 10 and in a family with other cancer susceptibility 9. In this study, we report the effects of the egfr tki gefitinib on expression of the antiapoptotic protein survivin that have. Main mechanisms of acquired resistance to egf receptor tyrosine kinase inhibitors. In this study, we prospectively explored the role of ctdna in detecting egfr mutations in patients plasma and determined the efficacy of egfr tyrosine kinase inhibitors tkis in patients with suspected advanced lung cancer, in the absence of pathologic diagnosis. Outcome of uncommon egfr mutation positive newly diagnosed. Epidermal growth factor receptor egfr is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the. Here, we report the efficacy and safety of osimertinib in patients with nsclc harboring uncommon egfr mutations. Familial lung cancers more likely have concurrent egfr mutations along with mutations in their germline cancer predisposition genes including. The availability of 3 generations of epidermal growth factor receptor egfr tyrosine kinase inhibitors tkis with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of egfr mutation positive nonsmallcell lung cancer. The discovery of driver mutations in lung cancer allows the creation of personalized targeted treatment.
The aim of this study was to find a correlation between morphological changes and egfr mutational status using both immunohistochemistry and molecular techniques. Osimertinib for patients with nonsmallcell lung cancer. Growth factor receptor egfr gene mutations in a chilean cancer center. Tyrosine kinase inhibitors for the treatment of egfr. Rare epidermal growth factor receptor egfr mutations in nonsmall cell lung cancer article pdf available in seminars in cancer biology september 2019 with. Epidermal growth factor receptor tyrosine kinase inhibitors egfr. In nonsmall cell lung cancer, overexpression of egfr or mutations in intracellular egfr have been observed in 4389% of cases 5. Molecular dynamics simulationguided drug sensitivity.
If you receive a lung cancer diagnosis, the very first thing you should do is make sure your doctors have ordered comprehensive biomarker testing done on your lung cancer tumor. Lung cancer patients with mutations in the egfr gene represent a significant amount of patients diagnosed with nonsmall cell lung cancer. Management of acquired resistance to egfr tkitargeted. Egfr mutation analysis in sputum of lung cancer patients. It is important that lung cancer patients are tested for oncogenic drivers of cancer and receive matched targeted therapy 4.
Identification of egfr mutations in cytological specimens of non. Epidermal growth factor receptor mutations in lung cancer. Potential genetic modifiers for somatic egfr mutation in lung cancer. Egfr mutations in patients with brain metastases from lung. Germline exon 21 egfr mutations, v843i and p848l, in. The egfr mutations of 70 nsclc patients were determined by. Both the aforementioned mutations result in changes. Nonsmallcell lung cancer nsclc, the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and. Targeting specific cancers in the lungs in the past, doctors thought that all lung cancers were pretty much the same. Treatment of uncommon egfr mutations in nonsmall cell. Prevalence of egfr mutations in lung cancer in uruguayan. Egfr mutations are usually observed in lung cancer as more than 60% of the nonsmall lung carcinoma cells overexpress egfrs da cunha santos et al.
Egfr mutations prevalence in chilean lung cancer patients. Nonsmall cell lung cancer targeted therapy lung cancer. Some, but not all, lung cancers carrying such mutations are responsive to treatment with smallmolecule egfr inhibitors, including the two fdaapproved drugs erlotinib and gefitinib. The impact of rare egfr mutations on the treatment. Management of egfr mutation positive metastatic nonsmall cell lung cancer leora horn, md, msc vanderbiltingram cancer center rogerio lilenbaum, md yale cancer centersmilow cancer hospital egfr mutation in advanced nsclc. The most common mutations are dele746a750 in exon 19 and l858r in exon 21, accounting for. Advanced nonsmallcell lung cancer nsclc is the leading cause of cancer related deaths in the world. Nonsmall cell lung cancer nsclc represents approximately 85 % of lung cancer cases and about 75 % of them are diagnosed in advanced nsclc ansclc i. In preclinical studies, bevacizumab as a single drug or in combination with erlotinib inhibited tumour growth of h1975 xenografts bearing egfr l858r and t790m mutations. A the t790m mutation affects the binding pocket of atp to the egfr, causing a steric hindrance that reduces the capability of egfr tyrosine kinase inhibitors tkis to. Egfr mutations as a prognostic and predictive marker in. Role of survivin in egfr inhibitorinduced apoptosis in. Nsclc patients with activating epidermal growth factor receptor egfr mutations, such as exon 19 deletion and exon 21 point mutation l858r, respond signi.
Epidermal growth factor receptor in nonsmall cell lung cancer ncbi. Recently, the study of the egfr mutations in lung cancer has become mandatory due to their usefulness in target therapy. Sensitizing mutations in epidermal growth factor receptor egfr are associated with positive responses to antiegfrtargeted therapy, leading to a new era of treatment for nonsmall cell lung cancer nsclc. Egfr mutation and resistance of nonsmallcell lung cancer. Nccn, florida 2016 rogerio lilenbaum, md professor of medicine yale cancer center chief medical officer smilow cancer hospital. Approximately 1015% of patients with nonsmall cell lung cancer in the united states and 35% in asia have an egfr positive mutation. Egfr mutant lung cancer patients whose tumors had tmb in the upper tertile had. Pdf receptor tyrosine kinase genes were sequenced in nonsmall cell lung cancer nsclc and matched normal tissue. Targeted therapy using egfr inhibitors has become the standard of care for nonsmall cell lung cancers that contain activating egfr mutations 3, even though not all patients with egfr mutations.
Egfr mutation testing usually focuses on common mutations like the exon 19 deletion and exon 21 point mutation l858r. Germline exon 21 egfr mutations, v843i and p848l, in nonsmall cell lung cancer patients to the editor. These results suggest that egfr mutations may predict sensitivity to gefitinib. Lung cancer is the leading cause of cancer related deaths. This recommendation is not intended to affect treatment with osimertinib that was started in the nhs before this guidance was published. What you need to know about lung cancer and egfr mutations.
1081 1206 1379 987 1501 1568 1066 462 1520 37 190 1464 398 1242 253 785 701 1185 455 3 383 1075 386 546 543 821 1186 1101 901 1365 322 890